Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (1048) clinical trials

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma

This is a Phase I/Ib, open-label, safety, and pharmacodynamics study of pembrolizumab in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma. This clinical study will be composed of a Dose Finding Phase and an Expansion Phase. The Dose Finding Phase will estimate the Recommended Phase II ...


A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

This is a single arm, single center, open-label, Phase 1, first time in human study of COTI-2 in patients with recurrent ovarian,fallopian tube,primary peritoneal cancer, endometrial, cervical or head and neck cancer. COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free ...


Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

A Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial Primary Objective: To determine progression free survival for mFFX +/- SBRT. Secondary Objectives: To determine metastasis free survival following mFFX chemotherapy alone or with SBRT. To determine the overall survival in pancreatic cancer patients treated with chemotherapy +/- SBRT. To determine local ...


A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors

DFP-11318 is an investigational drug product that has demonstrated reasonable antitumor activity in preclinical colorectal, gastric and lung tumor models in animals. This is a first in human trial to determine the maximum, safest dose of DFP-11318 IV that can be administered to patients either once every 3 weeks or ...


Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Screen and recruitment: patients will be screened based on their prior history and intention to initiate treatment with an immune checkpoint inhibitor. This screening of candidate patients by the investigators will be non-interventional. Patients that are considered eligible candidates will be invited to participate in this study and to Page ...

Phase N/A

Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer

Currently, FOLFIRINOX is considered the standard treatment for PS 0 or 1 patients with advanced pancreatic carcinoma. However, due to excessive toxicity dose reductions and interruptions in the treatment toxicity are frequent. So, for those not eligible patients (PS 2 or 3, hyperbilirubinemia, among other causes), alternative schemes as gemcitabine ...


Study of RC48-ADC in Patients With HER2-Positive Advanced Malignant Solid Tumors

A tolerance, safety and pharmacokinetic ascending dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive malignant in Advanced Malignant solid Tumors.


Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. There is an urgency for improving management, but there is no consensus on ...

Phase N/A

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

This is a Phase 2, single arm study of a tailored immunotherapy approach with nivolumab in adult ( 18 years) subjects with previously untreated (1st line) or pretreated (2nd and 3rd line), surgically unresectable or metastatic TCC (further designated "advanced TCC"). The study targets to recruit 130 untreated (1st line) ...


Low-dose Radiotherapy Plus Chemotherapy With GemOx and Stereotactic Radiotherapy for Advanced Pancreatic Cancer

Aim of this study is to evaluate if low-dose radiotherapy (LDR) can intensify local effect of a chemotherapy regimen with Gemcitabine and Oxaliplatin administered sequentially with stereotactic body radiotherapy (SBRT) and to assess the safety and efficacy of this combined treatment on patients affected by locally advanced pancreatic adenocarcinoma (LAPC).

Phase N/A